Organogenesis Holdings (2PQ) Q2 2026 Earnings Report

The call presented meaningful operational and clinical positives — sequential revenue recovery, strong clinical trial results (PuraPly AM and Affinity), FDA acceptance of the Amnuvx BLA and tangible cost-reduction measures — but these are outweighed by significant near-term financial stress: severe year-over-year revenue declines (≈58%), large operating and GAAP net losses, a halved cash position since year-end, lowered full-year revenue guidance, and deferred product launch timing to preserve cash. Management is focused on evidence-driven market share gains and expects improving adjusted EBITDA by Q4, but the company remains in a substantial recovery phase with execution and financing risks in the near term.

Organogenesis updated 2026 guidance calling for total net revenue of $179M–$215M (a 62%–68% YoY decline) — with Advanced Wound Care sales of $151M–$183M, Surgical & Sports Medicine $26M–$30M and $1.9M of grant income — and expects sequential improvement in Q3 and Q4 but a second‑half YoY revenue decline of roughly 64%–74%. Management expects improving adjusted EBITDA quarter‑to‑quarter, targeting nearly a 60% reduction in adjusted EBITDA loss in 2H vs 1H at the low end and >90% reduction at the high end (including positive adjusted EBITDA in Q4); it plans to cut operating expenses (ex‑COGS) ~32% YoY in 2026 and >40% YoY in 2H. Cost actions include a June workforce reduction of 138 employees (≈$18M annualized savings), March and June restructurings together expected to reduce annual operating expenses by >$32M, estimated 3Q/4Q savings of ~$7M and ~$9M respectively; cash was $46.8M at 6/30/26 with no debt, an ATM facility up to $75M, and management believes cash plus product cash flows will fund operations for at least the next 12 months.